Trial · NCT07882641
BEX101 in B-cell Non-Hodgkin's Lymphoma
NCT07882641, Phase 1, Phase 2, Recruiting, Chinese PLA General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. BEX101 in B-cell Non-Hodgkin's Lymphoma. Trials, record NCT07882641. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882641
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- BEX101 in B-cell Non-Hodgkin's Lymphoma
- NCT number
- NCT07882641
- Status
- Recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Chinese PLA General Hospital
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- BEX101 injection
- First posted
- 2026-10-20
- Last updated
- 2026-10-22
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose limited toxicity (DLT) (phase 1) | Within 28 days post-infusion | DLT is defined as any of the following adverse events (AEs) related to BEX101 injection infusion occurring within 28 days after BEX101 injection infusion (CRS and ICANS will be graded according to the ASTCT 2019 criteria, and other AEs will be evaluated using CTCAE v6.0): * Grade ≥ 3 neurotoxicity and/or CRS that does not resolve to Grade ≤ 2 within 7 days after therapeutic intervention; * Grade ≥ 3 non-hematologic toxicities other than CRS and neurotoxicity that do not resolve to Grade ≤ 2 within 14 days despite appropriate clinical treatment and management, excluding clinically insignificant laboratory abnormalities; * Grade ≥ 4 hematologic toxicities, including decreased neutrophil count and decreased platelet count, persisting for \> 28 days after infusion of BEX101 injection. |
| Primary | Incidence and severity of AEs and serious AEs (SAEs) (phase 1) | Within 24 months post-infusion | AEs refer to any adverse medical events occurring in subjects from the initiation of BEX101 administration during clinical trials. SAEs denote events involving death, life-threatening conditions, significant disability/incapacity, hospitalization or prolonged hospitalization arising after BEX101 administration in subjects. |
| Primary | Incidence and severity of AEs of special interest (AESI) (phase 1) | Within 24 months post-infusion | AESI including grade ≥ 3 CRS, ICANS, and infections |
| Primary | Objective Response Rate (ORR) (phase 2) | Within 24 months post-infusion | ORR includes CR and PR. |
| Secondary | Incidence and severity of AEs (phase 2) | Within 24 months post-infusion | AEs refer to any adverse medical events occurring in subjects from the initiation of BEX101 administration during clinical trials. |
| Secondary | ORR (phase 1) | Within 24 months post-infusion | ORR includes CR and PR. |
| Secondary | Duration of Response (DOR) (phase 1 and phase 2) | Within 24 months post-infusion | Time from first documented PR or CR to relapse or disease progression, or death from any cause. |
| Secondary | Progression-Free Survival (PFS) (phase 1 and phase 2) | Within 24 months post-infusion | Time from administration to disease progression or death from any cause, which ever occurs first. |
| Secondary | Overall Survival (OS) (phase 1 and phase 2) | Within 24 months post-infusion | Time from administration to death from any cause. |
| Secondary | Number of CAR-positive T cells (phase 1 and phase 2) | Within 24 months post-infusion | Number of CAR-positive T cells in peripheral blood. |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882641
GET https://conductscience.org/api/trials/v1/NCT07882641/registered